Niemann-Pick type C (NPC) disease is a rare and fatal inherited metabolic disorder that results in intracellular accumulation of cholesterol and glycolipids within the endosomal/lysosomal system. Central nervous system (CNS) involvement is especially prominent as evidenced by ataxia and progressive decline of motor skills and intellectual function. Defects in either the NPC1 or NPC2 protein, both of which are thought to be involved in the egress of cholesterol and other lipids out of the endosomal/lysosomal system, leads to NPC disease. The pathogenic cascade is not well understood, and currently there is no corrective therapy for NPC patients. However, some compounds tested in animal models of NPC disease have shown promise in slowing disease onset and progression, and administration of these drugs in combination has provided evidence of synergy and enhanced clinical benefit. This favorable outcome indicates that combinatorial therapies using small molecules likely represent the best therapeutic option available to NPC patients at this time.
Lysosomal diseases are rare metabolic disorders that result from inherited defects in the endosomal/lysosomal system and often lead to severe clinical disease and premature death. The endosomal/ lysosomal system is a vital recycling center that plays a critical role in intracellular signaling and homeostatic events, including a primary role in the breakdown and salvage of most cellular components. other well-known pathologic changes, including the formation of meganeurites, the growth of ectopic dendrites, and the widespread occurrence of neuroaxonal dystrophy. 3 Patients with NPC disease typically present with vertical supranuclear gaze palsy (VSGP) and learning difficulties, followed by ataxia, seizures, dystonia, respiratory dysfunction, and progressive mental decline. 1, [4] [5] [6] Most patients succumb to NPC disease in adolescence, although disease onset is variable and adult-onset cases of NPC disease have been reported. 7 
Niemann-Pick Type C Disease-A Brief History
The discovery of Niemann-Pick disease is attributed to Albert
Niemann, a German pediatrician, and Ludwig Pick, a German pathologist. In 1914, Niemann provided a report of a child with CNS impairment and enlarged liver and spleen (hepatosplenomegaly). onset and severity of disease. Type A typically presents in infants and is characterized by severe neurologic involvement, while type B presents later (juvenile) and has little to no neurologic involvement. 10, 11 In reality, many patients lie somewhere along a continuous spectrum of the two disease types. 12 While both NPA and NPB are pan-ethnic and have an incidence of approximately 0.5-1:100,000, NPA is known to occur more frequently among individuals of Ashkenazi Jewish decent. 13 Niemann-Pick types C and D (NPC and NPD) have recently been determined to be genetically equivalent (now collectively known as NPC disease) and distinct from types A and B. NPC disease is also mice have also been shown to be deficient in the production of neurosteroids, specifically allopregnanolone, presumably as a result of altered cholesterol egress from lysosomes. 31 Recently, work on NPC Although many neurons are able to survive the above myriad morphological changes and cellular insults for years, neurodegeneration does occur in NPC disease, the most notable example being the patterned cell death of PCs in the cerebellum. 35 As PCs represent the sole output of the cerebellar cortex, PC dysfunction and death likely plays a key role in ataxia and other motor impairments present in NPC patients.
Why PCs exhibit this selective vulnerability to neurodegeneration is unknown, but it has recently been hypothesized that the early and prominent development of neuroaxonal dystrophy affecting these neurons may be responsible by depriving them of essential growth factors for survival.
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Clinical Manifestations
Clinical signs and progression of NPC disease vary from patient to patient. It has generally been considered that disease progression in NPC and other lysosomal diseases correlates to age of onset, with earlier clinical onset normally leading to a more rapid progression and earlier death. The hallmark clinical signs of NPC disease are considered to be VSGP and ataxia, although not all patients present with these two abnormalities. In fact, patient phenotypes can be loosely categorized based on age at disease onset. 1 Peri-natal-onset patients usually present with fetal ascites, neonatal jaundice, and hepatosplenomegaly.
Early infantile patients may also exhibit hepatosplenomegaly in addition to hypotonia and a general delay in development of normal motor function. Late-infantile-onset generally presents with clumsiness and ataxia and occasionally organomegaly and VSGP. Juvenile patients most commonly experience behavioral problems, learning difficulties, and ataxia, as well as VSGP, dysarthria, dystonia, seizures, and cataplexy.
Finally, adolescent-and adult-onset disease is characterized by ataxia, dementia, psychosis, and a general progressive neurologic decline.
VSGP may or may not be present in older patients. Sleeping problems and/or narcolepsy as well as respiratory distress are other issues commonly encountered in NPC patients and pulmonary complications are commonly the cause of death.
Animal Models
Animal models have been and continue to be an invaluable resource in the quest to understand the NPC defect and resulting pathogenic cascades, as well as to test the efficacy and safety of possible treatments. There is an established feline colony of NPC1 disease, as well as three murine (BALB/cNctr-Npc1 m1N /J, C57BLKS/J-Npc1 spm /J, and Npc2 -/-) models of NPC disease. With the exception of the NPC2 murine model, which was generated by targeted disruption of NPC2
and resulted in a severe hypomorph, 19 all models arose from spontaneous mutations in the Npc1 gene. Based on this latter theory, statins and cholesterol-lowering diets would not be expected to benefit NPC patients.
Enzyme replacement therapy (ERT), or intravenous administration of functional enzyme to patients, is currently used to treat Besides ERT, bone marrow transplantation (BMT) or stem cell therapy also offers potential cell-mediated correction of some lysosomal diseases. 43 The therapeutic efficacy of BMT relies heavily on cross-correction of diseased cells by donor cells. Again, it is unlikely that NPC1 disease would be corrected since this therapy requires protein secretion and uptake.
BMT was performed in a NPC1 patient who was 2.5 years of age, resulting in full engraftment that led to reduced pathology in the liver, spleen, and lung 44 (likely a reflection of a normalization of macrophages). However, there were no improvements in neurologic function, consistent with the view that BMT is unlikely to correct the NPC1 defect. 44 A different strategy, chaperone-mediated therapy, relies on the assistance of small molecules or upregulation of endogenous chaperones and related molecules to properly fold, stabilize, and/or traffic partially functioning or misfolded proteins. 46, 47 Although there are no harmacologic chaperones currently used for the treatment of NPC disease, there is evidence that some mutated NPC proteins are targeted for endoplasmic reticulum-associated degradation (ERAD) due to protein misfolding. 48 This suggests that potent small-molecule chaperones may be of benefit to patients harboring specific mutations in which the NPC protein is misfolded. Alternately, smallmolecule therapy designed to correct defective metabolic pathways may also be a viable therapeutic option for NPC disease. For example, administration of the synthetic ligand T0901317, which was shown to increase liver X receptor-β (LXR-β) activity in the brain of NPC1 mice, was reported to provide modest slowing of neurodegeneration and to prolong life. 49 This small molecule was suggested to enhance net sterol excretion from the brain, as LXR-β is a ligand-activated transcription factor involved in regulation of sterol metabolism. 49 In other studies, upregulation of Rab9, a small GTPase protein Neurodegeneration is another potential target for treatment of NPC disease. In an effort to prevent neuronal cell death in NPC1 mice, researchers administered imatinib, a c-Abl-specific inhibitor that reduces apoptosis. Treated NPC1 mice were reported to show improved neurological symptoms, moderately increased lifespan, and rescue of PCs in the cerebellum. 57 In other work, sphingosine, one of several lipids believed to accumulate in NPC disease, has been suggested to cause abnormally low calcium levels in the acidic compartments of NPC1 cells. Treatment of NPC1 mice with curcumin, a drug thought to be capable of elevating cytosolic calcium levels and purportedly overcoming late endosomal/lysosomal transport defects, showed benefits in terms of reduced tremors and increased activity, as well as a modest increase in lifespan. 58 As NPC disease is characterized by the storage of unmetabolized cellular components, reducing or preventing the accumulation of these offending metabolites offers a means by which cellular metabolic burden can be decreased. This method of treatment is known as substrate reduction therapy (SRT). 59 In theory, this goal can be achieved by partially inhibiting the biosynthesis of selected cellular compounds so that the rate of synthesis is more closely matched to the rate of degradation.
The most notable example of SRT to date is N-butyldeoxynojirimycin, or miglustat, a small amino sugar that partially inhibits the synthesis of GSLs, a known storage product in NPC and other lysosomal disorders such as Gaucher disease. 60, 61 In both murine and feline studies, administration of miglustat has led to a delay in the onset of clinical signs and to an increase in lifespan. 60 Qualitative studies examining GM2
and GM3 gangliosides also suggested a reduction in storage of these Byproduct replacement therapy is another potential treatment for lysosomal diseases, the objective being to replace cellular products found to be deficient in particular diseases. 65 This concept was based on the finding that allopregnanolone was deficient in NPC1 mice and administration of this neurosteroid in early development was thought to delay onset of clinical symptoms and significantly increase lifespan. 31 Subsequent studies showed that the agent responsible for the beneficial effect seen in NPC1 mice was actually the vehicle 2-hydroxypropyl-beta-cyclodextrin (HPBCD). 66, 67 While byproduct replacement therapy has yet to be validated as a treatment for NPC disease, it did lead to the discovery of HPBCD as a therapeutic agent.
Cyclodextrins are cyclic sugar molecules commonly utilized as delivery agents for poorly soluble drugs. 68 The inner hydrophobic pocket can form a guest:host complex with drugs or other compounds of interest that are then easily solubilized due to the hydrophilic outer ring of the cyclodextrin molecule. HPBCD is also known to bind cholesterol and is frequently used to add or extract cholesterol in cultured cells. 68, 69 When administered to either NPC1 or NPC2 mice at early ages, significant benefits are seen in terms of the delayed onset of clinical signs, reduced storage of both cholesterol and GSLs, and increased lifespan. 66 Additionally, single injections of HPBCD at post-natal day seven or 49
have been shown to significantly improve liver function and increase lifespan. 67 The mechanism of action of HPBCD is unknown and studies have yet to confirm whether it actually crosses the BBB to exert its effect. However, it is well established that intraneuronal accumulation of both cholesterol and gangliosides is diminished with HPBCD treatment and that lifespan is increased beyond that seen with any other current monotherapy. 66, 67 Several of the therapies discussed above provide limited benefit to NPC patients or animal models of NPC disease when administered alone.
However, they are by no means a cure and each therapy tends to address only one or a few elements in the pathogenic cascade (see Figure 1 ). As such, a logical approach to treatment of NPC disease, as well as many other diseases, is that of combination therapy. Her work focuses on understanding the mechanism of action of cyclodextrin, a drug that she and others discovered as having an ameliorating effect on NPC disease. She is also interested in combination therapies in NPC murine models to achieve greater benefit, with the hope that these therapies can benefit children with this disorder. 
